Physician profile
Dongjin Sung
NPI 1114231198
$3,729.58
in general payments reported to CMS, 2019-2025
21 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $166 · 2021: $130 · 2022: $218 · 2023: $684 · 2024: $765 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $993.41 | 2023-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $526.74 | 2020-2025 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $439.39 | 2021-2025 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals LP | $408.75 | 2020-2025 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $176.47 | 2019-2021 | |
| Pfizer INC. | $175.39 | 2019-2025 | |
| Novo Nordisk INC | $126.70 | 2019-2025 | Ozempic, Rybelsus |
| Scilex Pharmaceuticals INC. | $126.61 | 2019-2025 | |
| Mylan Specialty L.P. | $123.26 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.45 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $91.37 | 2023-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $90.01 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $83.18 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $53.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.45 | 2023-2024 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $44.86 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $24.33 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $21.40 | 2025 | Shingrix, Arexvy |
| Janssen Biotech, INC. | $19.88 | 2025 | Stelara, Tremfya, Simponi |
| Sumitomo Pharma America, INC. | $19.84 | 2025 | Gemtesa |
| Alk-Abello, INC | $16.59 | 2024 | Grastek, Odactra, Ragwitek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dongjin Sung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.